losudesivir   Click here for help

GtoPdb Ligand ID: 14618

Compound class: Synthetic organic
Comment: Losudesivir is the INN for an adenosine analogue that is intended as a coronavirus antiviral agent. The structure was obtained from WHO INN Proposed List 135 (July 2026). It represents an orally bioavailable RdRp inhibitor known by the codes SHEN26 and ATV014 that exhibits broad-spectrum activity against multiple coronaviruses [3-5]. Structurally, losudesivir is a cyclohexane carboxylate prodrug of the parent compound and active metabolite of remdesivir, GS-441524. Mechanistically RdRp inhibitors disrupt viral nucleic acid synthesis and thereby replication.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 10
Hydrogen bond donors 3
Rotatable bonds 5
Topological polar surface area 153.76
Molecular weight 401.42
XLogP -0.32
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1CCC(CC1)C(=O)OC[C@@H]2[C@H]([C@H]([C@](C#N)(C3=CC=C4C(=NC=NN43)N)O2)O)O
Isomeric SMILES C1CCC(CC1)C(=O)OC[C@@H]2[C@H]([C@H]([C@](O2)(C#N)C3=CC=C4N3N=CN=C4N)O)O
InChI InChI=1S/C19H23N5O5/c20-9-19(14-7-6-12-17(21)22-10-23-24(12)14)16(26)15(25)13(29-19)8-28-18(27)11-4-2-1-3-5-11/h6-7,10-11,13,15-16,25-26H,1-5,8H2,(H2,21,22,23)/t13-,15-,16-,19+/m1/s1
InChI Key NJZZWWHRMAGFGB-ZIGSKRJUSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
SHEN26 was progressed as a clinical candidate for the treatment of COVID-19.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05504746 A Phase I Study of SHEN26 Capsule in Healthy Participants Phase 1 Interventional Kexing Biopharm Co., Ltd. 2
NCT05676073 Study of SHEN26 Capsule in Patients With Mild to Moderate COVID-19 Phase 2 Interventional Kexing Biopharm Co., Ltd. 1